Richard A. Heyman sold $87k of ORIC
director at Oric Pharmaceuticals, Inc.. 6,700 shares at an average of $12.91, traded Oct 1, 2026, filed Oct 2, 2026.
Score components
- +15RoleDirector
- +9Trade size$87k at market
- +5Share of holdings soldSold 16% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001584759-26-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +3,500 | $1.60 | $5,600 | 41,800 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,500 | $12.91 | $45k | 38,300 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,200 | $12.91 | $41k | 203,472 | 10 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,500 | $0.00 | $0 | 26,700 | 10 d ago |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 35Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $1.3M 125,000 shares | -16% | |
| 27Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $351k 33,500 shares | -33% | |
| 40Moderate | ORICbuy Oric Pharmaceuticals, Inc. | Angie You director | $263k 28,000 shares | - | |
| 2Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $3,000 300 shares | -0% | |
| 8Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $33k 3,300 shares | -3% | |
| 7Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $29k 2,900 shares | -3% | |
| 37Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $204k 24,660 shares | -3% | |
| 28Weak | Oric Pharmaceuticals, Inc. | Pratik S Multani Chief Medical Officer | $73k 8,850 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.